You are viewing: Australia Humanized Mouse and Rat Model Market analysis

The Australia Humanized Mouse and Rat Model Market was valued at $2.3 Million in 2025 and projected to reach to $2.5 Million by 2030, representing a compound annual growth rate of 1.9%. Australia's humanized mouse and rat model market is positioned for steady growth driven by ongoing investments in biomedical research and the country's commitment to advancing pharmaceutical development.

Australia Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Humanized Mouse and Rat Model Market Trends and Insights

  • Australia's market reflects steady but modest growth compared to global trends, driven by the country's established pharmaceutical and biotechnology research infrastructure.
  • The adoption of humanized animal models in Australia is supported by regulatory frameworks and investment in preclinical research capabilities across major research institutions and contract research organizations (CROs). Australia's position within the Asia Pacific region positions it as a secondary but important hub for drug development and toxicology studies.
  • The market in Australia benefits from collaborations between domestic research facilities and international pharmaceutical companies seeking reliable preclinical testing platforms.
  • While Australia's 1.9% CAGR is lower than the global average of 8.2%, the country maintains consistent demand for humanized models in oncology, immunology, and infectious disease research through 2030..

Key Market Statistics

  • CAGR (2025-2030) 1.9% CAGR
  • Market Size, 2025 ~USD 2.3 Million
  • Forecast, 2030 ~USD 2.5 Million
  • Country Australia

Australia Humanized Mouse and Rat Model Market Overview

Market Valuation :

Australia's humanized mouse and rat model market is valued at USD 2.3 million in 2025, with projections to reach USD 2.5 million by 2030.

Growth Rate :

The Australian market is expanding at a CAGR of 1.9% through 2030, reflecting steady but modest growth compared to the global CAGR of 8.2%.

Research Infrastructure :

Australia's established pharmaceutical and biotechnology research infrastructure supports consistent adoption of humanized animal models in preclinical studies and drug development.

Market Maturity :

As a developed market with mature research capabilities, Australia demonstrates stable demand from academic institutions, contract research organizations, and pharmaceutical companies.

Australia Humanized Mouse and Rat Model Market Dynamics

  • The modest CAGR of 1.9% reflects a mature market with established adoption patterns among research institutions and pharmaceutical companies.
  • Increasing focus on personalized medicine and translational research is expected to sustain demand for humanized models in preclinical testing.
  • However, growth remains constrained compared to global markets due to Australia's smaller research population and limited venture capital funding relative to larger economies.
  • Strategic partnerships with international research organizations and government support for life sciences innovation will be critical to accelerating market expansion beyond current trajectories..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Australia's humanized mouse and rat model market is valued at USD 2.3 million in 2025 with a projected value of USD 2.5 million by 2030.
    • Australia's market growth rate of 1.9% CAGR is significantly lower than the global average of 8.2%, indicating a mature but stable market.
    • Australia's research infrastructure and regulatory environment support steady demand for humanized models in pharmaceutical development and preclinical testing.
    • Australia's market is characterized by collaborations between domestic CROs and international pharmaceutical companies seeking reliable preclinical research platforms.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    Australia Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC AND RESEARCH INSTITUTES0.440.440.440.450.460.460.460.460.7
    CROS & CDMOS0.730.730.750.780.80.820.830.842.2
    PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES1.61.591.631.681.711.731.741.741.3
    TOTAL2.782.762.832.912.973.013.033.041.5

    Target Audience

    • Pharmaceutical Companies : Australian and international pharma firms need market data to assess demand for humanized models in preclinical development and optimize R&D investments in the region.
    • Contract Research Organizations (CROs) : CROs operating in Australia require localized market insights to evaluate service demand, pricing strategies, and capacity planning for humanized model services.
    • Biotech and Research Institutions : Academic and research organizations need market forecasts to justify funding requests, plan research programs, and understand adoption trends for humanized animal models.
    • Model Suppliers and Vendors : Suppliers of humanized mice and rats need Australia-specific market data to identify growth opportunities, assess market penetration, and develop regional sales strategies.
    • Investment and Venture Capital Firms : Investors evaluating opportunities in Australia's life sciences sector need market intelligence to assess the viability and growth potential of humanized model-related ventures.

    Key Companies in the Australia Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Localized Market Intelligence : Gain Australia-specific insights into market size, growth trajectories, and regional dynamics that differ significantly from global trends, enabling targeted business strategies.
    • Competitive Landscape Analysis : Understand the competitive positioning of humanized model suppliers and research organizations operating within Australia's pharmaceutical and biotech ecosystem.
    • Investment Decision Support : Make informed investment and expansion decisions with detailed forecasts through 2030, identifying growth opportunities in Australia's stable but emerging research market.
    • Regulatory and Infrastructure Context : Access insights into Australia's research infrastructure, regulatory environment, and institutional adoption patterns that influence market dynamics and growth potential.
    • Strategic Partnership Opportunities : Identify key stakeholders, research institutions, and pharmaceutical companies in Australia driving demand for humanized models to inform partnership and collaboration strategies.

    Frequently asked questions

    What is the current market size of humanized mouse and rat models in Australia?

    Australia's humanized mouse and rat model market is valued at USD 2.3 million in 2025 and is expected to reach USD 2.5 million by 2030.

    What is the growth rate for Australia's humanized mouse and rat model market?

    Australia's market is growing at a CAGR of 1.9% from 2025 to 2030, which is lower than the global average of 8.2%.

    Why is Australia's market growth slower than the global average?

    Australia's market is mature and stable with established research infrastructure, resulting in steady but modest growth compared to emerging markets in the Asia Pacific region.

    Which therapeutic areas drive demand for humanized models in Australia?

    Australia's demand for humanized models is primarily driven by oncology, immunology, and infectious disease research conducted by pharmaceutical companies and research institutions.

    Who are the key users of humanized mouse and rat models in Australia?

    Key users in Australia include contract research organizations (CROs), pharmaceutical companies, academic research institutions, and biotech firms engaged in preclinical drug development.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status